Post-cycle therapy (PCT) is the set of drugs people take after a course of exogenous androgens to help their own testosterone production restart. It exists because taking testosterone or other anabolic steroids switches off the body's own production, and that switch does not always flip back on quickly by itself. This guide covers the biology of that shutdown, the two main tools used to reverse it, and what the published evidence does and does not support. It is reference information, not medical advice.
Before going further, it helps to be honest about the evidence base. Most formal PCT research comes from two places: fertility medicine, where SERMs and hCG are used to restart sperm and testosterone production in men, and studies of hormonal male contraception, where researchers deliberately suppressed and then recovered the axis. There are very few controlled trials of PCT as bodybuilders actually run it. So the mechanisms below are well established, but the specific protocols and timelines are extrapolated, and much of the fine detail is anecdote.
Why the axis shuts down
Testosterone production is governed by a feedback loop called the hypothalamic-pituitary-gonadal (HPG) axis, often called the HPTA when the testes are the focus. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses. That tells the pituitary to release two hormones: luteinising hormone (LH) and follicle-stimulating hormone (FSH). LH drives the Leydig cells in the testes to make testosterone; FSH, together with high local testosterone, drives sperm production in the Sertoli cells.
The loop is self-regulating. When testosterone and estradiol rise, they signal the hypothalamus and pituitary to slow down GnRH and LH. When you inject exogenous testosterone, blood levels rise far above normal, so the brain reads the signal as 'plenty of testosterone here' and shuts down its own GnRH and LH output. With no LH signal, the Leydig cells go quiet and intratesticular testosterone collapses, which is why the testes shrink and sperm production falls during a cycle. Aromatisation of androgens to estradiol adds to the negative feedback, so estrogen is part of the shutdown too, not just testosterone.
What PCT is trying to fix
PCT is not one thing. It is trying to solve two related but distinct problems:
- Restarting the brain's signal: getting the hypothalamus and pituitary to release GnRH and LH again after they have been suppressed.
- Restoring the testes' ability to respond: making sure the Leydig cells can still make testosterone once the LH signal returns.
SERMs address the first problem. hCG addresses the second. They work at different points in the loop, which is why they are sometimes used together and why one is not a substitute for the other.
What SERMs actually do
Selective estrogen receptor modulators (SERMs) such as tamoxifen and clomifene block estrogen receptors in the hypothalamus and pituitary. Because estrogen is a major brake on the axis, blocking that brake makes the brain think estrogen is low, so it ramps GnRH, LH and FSH back up. The rising LH then stimulates the testes to resume testosterone production. In other words, a SERM does not add any testosterone; it removes a brake so your own production climbs.
Tamoxifen and clomifene are both triphenylethylene SERMs and both raise LH, FSH and testosterone in men in controlled studies. Tamoxifen tends to be viewed as gentler on mood and vision; clomifene is a mixture of two isomers (enclomifene and zuclomifene), and the long-lived zuclomifene isomer is blamed for some of clomifene's mood and visual side effects. Crucially, a SERM only works if the pituitary and testes are capable of responding. If the testes have been dormant for a long time, the SERM has nothing much to push on until they recover.
What hCG actually does
Human chorionic gonadotropin (hCG) is not a SERM and does not work on the brain at all. It is an LH-mimic: it binds the same receptor on the Leydig cells and directly tells the testes to make testosterone. This is why hCG can restore testicular size and intratesticular testosterone even while the brain is still suppressed.
That directness is also its limitation. Because hCG bypasses the brain, it does not help the hypothalamus and pituitary recover, and high or prolonged doses can actually keep the axis suppressed by raising testosterone and estradiol, which feeds back negatively. Excess hCG can also desensitise the Leydig cells. For that reason hCG is most defensibly used before or early in a restart, to wake up shrunken testes, and is then stopped so a SERM can drive the brain's own recovery. Using hCG right up to and through PCT can be self-defeating.
Aromatase inhibitors are not PCT
Aromatase inhibitors (AIs) such as anastrozole block the conversion of androgens to estrogen. They are used on-cycle to manage estrogen and, occasionally, at low doses alongside a restart. But an AI is not itself a recovery drug, and crushing estradiol during PCT is counterproductive: low estradiol worsens libido, joints, lipids and mood, and the goal of recovery is a normal axis, not a suppressed-estrogen one. Some restart protocols avoid AIs entirely unless estrogen is genuinely symptomatic.
A typical framework
Protocols vary enormously and none is validated in a trial, but the common logic runs like this:
- Wait for the exogenous androgen to clear. Starting a SERM while long-ester testosterone is still high wastes it, because the exogenous hormone is still suppressing the axis. Timing is driven by ester half-life.
- Optionally use hCG for a couple of weeks beforehand if the testes are very shrunken, then stop it.
- Run a SERM (tamoxifen and/or clomifene) for roughly four to six weeks, often tapering the dose down.
- Retest blood work several weeks after finishing to confirm the axis has actually recovered rather than assuming it has.
Doses in the anecdotal literature are commonly in the range of tamoxifen 20-40 mg/day and clomifene 25-50 mg/day, tapering. These are not established as optimal; they are convention.
What the evidence supports, and what it doesn't
Well supported: SERMs raise LH, FSH and testosterone in men; hCG directly stimulates testicular testosterone; both are used clinically to recover the axis and fertility. What is weak: the specific combinations, doses, durations and timing used in bodybuilding PCT have essentially no controlled trial support, and 'natty test back to baseline in four weeks' is an expectation, not a finding. Recovery is real but often slower and messier than the standard four-week protocol implies, particularly after long or heavy use.
Bottom line
PCT works on a feedback loop: SERMs like tamoxifen and clomifene take the brake off the brain so your own LH and testosterone climb, while hCG mimics LH to wake up the testes directly. They are complementary, not interchangeable, and neither is a guaranteed reset button. Aromatase inhibitors are for estrogen control, not recovery. The mechanisms are solid; the exact protocols are convention. The single most useful, evidence-based step is to confirm recovery with blood tests rather than assume it.